Immune activation and virologic response to immunization in recent HIV type 1 seroconverters

Edward N. Janoff, Sybil A. Tasker, Mario Stevenson, Jeffrey B. Rubins, James O'Brien, Greg Utz, Peter Weiss, Frank W. Hall, Mark R. Wallace

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Antigenic stimulation from invasive bacterial infections, and the vaccines designed to prevent them, may promote T cell activation and enhancement of HIV-1 replication. Changes in viral load have been correlated with antigen-specific responses. We prospectively determined the impact of immunization with 23-valent pneumococcal vaccine (PVAX) and Haemophilus influenzae type b (Hib)-modified diphtheria toxoid CRM197 (DT) vaccine on HIV-1 replication in recent HIV-1 seroconverters (n = 14; median, 5.5 months from infection; median CD4+ T cells, 535 μl), and correlated results with vaccine-related immune activation. Specific antibody responses, markers of CD4+ T cell activation (transferrin and interleukin 2 receptors), and viral burden were measured at weeks -2 (pre), 0, 1, 2, 6, and 12 after immunization. By week 2, levels of IgG had increased significantly over baseline in both HIV-l-infected patients and HIV-l-seronegative control subjects (n = 9) for each antigen (geometric mean fold rise: PVAX, 10.1 versus 5.3; Hib, 16.0 versus 11.7; and DT, 26.2 versus 24.5, respectively). Despite these vigorous responses to both polysaccharide and protein antigens, HIV-1-infected patients showed limited evidence of CD4+ T cell activation at 1 week, no consistent rise in HIV-1 burden at any point, and no decline in CD4+ T cell number over time. We conclude that recent HIV-1 seroconverters show vigorous humoral responses to vaccine antigens and limited early evidence of T cell activation, but no substantial or sustained increase in viral replication or decline in CD4+ T cell number. Thus, respiratory bacterial vaccines appear immunogenic and safe early in HIV-1 infection.

Original languageEnglish
Pages (from-to)837-845
Number of pages9
JournalAIDS Research and Human Retroviruses
Volume15
Issue number9
DOIs
StatePublished - Jun 10 1999
Externally publishedYes

Fingerprint

HIV-1
Immunization
T-Lymphocytes
Bacterial Vaccines
Diphtheria Toxoid
Antigens
Haemophilus influenzae type b
Vaccines
Viral Load
Cell Count
HIV
Pneumococcal Vaccines
Interleukin-2 Receptors
Transferrin
Bacterial Infections
HIV Infections
Antibody Formation
Polysaccharides
Immunoglobulin G
Infection

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. / Janoff, Edward N.; Tasker, Sybil A.; Stevenson, Mario; Rubins, Jeffrey B.; O'Brien, James; Utz, Greg; Weiss, Peter; Hall, Frank W.; Wallace, Mark R.

In: AIDS Research and Human Retroviruses, Vol. 15, No. 9, 10.06.1999, p. 837-845.

Research output: Contribution to journalArticle

Janoff, EN, Tasker, SA, Stevenson, M, Rubins, JB, O'Brien, J, Utz, G, Weiss, P, Hall, FW & Wallace, MR 1999, 'Immune activation and virologic response to immunization in recent HIV type 1 seroconverters', AIDS Research and Human Retroviruses, vol. 15, no. 9, pp. 837-845. https://doi.org/10.1089/088922299310746
Janoff, Edward N. ; Tasker, Sybil A. ; Stevenson, Mario ; Rubins, Jeffrey B. ; O'Brien, James ; Utz, Greg ; Weiss, Peter ; Hall, Frank W. ; Wallace, Mark R. / Immune activation and virologic response to immunization in recent HIV type 1 seroconverters. In: AIDS Research and Human Retroviruses. 1999 ; Vol. 15, No. 9. pp. 837-845.
@article{43ec0b2cdec04f4caba299ae1a829a0f,
title = "Immune activation and virologic response to immunization in recent HIV type 1 seroconverters",
abstract = "Antigenic stimulation from invasive bacterial infections, and the vaccines designed to prevent them, may promote T cell activation and enhancement of HIV-1 replication. Changes in viral load have been correlated with antigen-specific responses. We prospectively determined the impact of immunization with 23-valent pneumococcal vaccine (PVAX) and Haemophilus influenzae type b (Hib)-modified diphtheria toxoid CRM197 (DT) vaccine on HIV-1 replication in recent HIV-1 seroconverters (n = 14; median, 5.5 months from infection; median CD4+ T cells, 535 μl), and correlated results with vaccine-related immune activation. Specific antibody responses, markers of CD4+ T cell activation (transferrin and interleukin 2 receptors), and viral burden were measured at weeks -2 (pre), 0, 1, 2, 6, and 12 after immunization. By week 2, levels of IgG had increased significantly over baseline in both HIV-l-infected patients and HIV-l-seronegative control subjects (n = 9) for each antigen (geometric mean fold rise: PVAX, 10.1 versus 5.3; Hib, 16.0 versus 11.7; and DT, 26.2 versus 24.5, respectively). Despite these vigorous responses to both polysaccharide and protein antigens, HIV-1-infected patients showed limited evidence of CD4+ T cell activation at 1 week, no consistent rise in HIV-1 burden at any point, and no decline in CD4+ T cell number over time. We conclude that recent HIV-1 seroconverters show vigorous humoral responses to vaccine antigens and limited early evidence of T cell activation, but no substantial or sustained increase in viral replication or decline in CD4+ T cell number. Thus, respiratory bacterial vaccines appear immunogenic and safe early in HIV-1 infection.",
author = "Janoff, {Edward N.} and Tasker, {Sybil A.} and Mario Stevenson and Rubins, {Jeffrey B.} and James O'Brien and Greg Utz and Peter Weiss and Hall, {Frank W.} and Wallace, {Mark R.}",
year = "1999",
month = "6",
day = "10",
doi = "10.1089/088922299310746",
language = "English",
volume = "15",
pages = "837--845",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "9",

}

TY - JOUR

T1 - Immune activation and virologic response to immunization in recent HIV type 1 seroconverters

AU - Janoff, Edward N.

AU - Tasker, Sybil A.

AU - Stevenson, Mario

AU - Rubins, Jeffrey B.

AU - O'Brien, James

AU - Utz, Greg

AU - Weiss, Peter

AU - Hall, Frank W.

AU - Wallace, Mark R.

PY - 1999/6/10

Y1 - 1999/6/10

N2 - Antigenic stimulation from invasive bacterial infections, and the vaccines designed to prevent them, may promote T cell activation and enhancement of HIV-1 replication. Changes in viral load have been correlated with antigen-specific responses. We prospectively determined the impact of immunization with 23-valent pneumococcal vaccine (PVAX) and Haemophilus influenzae type b (Hib)-modified diphtheria toxoid CRM197 (DT) vaccine on HIV-1 replication in recent HIV-1 seroconverters (n = 14; median, 5.5 months from infection; median CD4+ T cells, 535 μl), and correlated results with vaccine-related immune activation. Specific antibody responses, markers of CD4+ T cell activation (transferrin and interleukin 2 receptors), and viral burden were measured at weeks -2 (pre), 0, 1, 2, 6, and 12 after immunization. By week 2, levels of IgG had increased significantly over baseline in both HIV-l-infected patients and HIV-l-seronegative control subjects (n = 9) for each antigen (geometric mean fold rise: PVAX, 10.1 versus 5.3; Hib, 16.0 versus 11.7; and DT, 26.2 versus 24.5, respectively). Despite these vigorous responses to both polysaccharide and protein antigens, HIV-1-infected patients showed limited evidence of CD4+ T cell activation at 1 week, no consistent rise in HIV-1 burden at any point, and no decline in CD4+ T cell number over time. We conclude that recent HIV-1 seroconverters show vigorous humoral responses to vaccine antigens and limited early evidence of T cell activation, but no substantial or sustained increase in viral replication or decline in CD4+ T cell number. Thus, respiratory bacterial vaccines appear immunogenic and safe early in HIV-1 infection.

AB - Antigenic stimulation from invasive bacterial infections, and the vaccines designed to prevent them, may promote T cell activation and enhancement of HIV-1 replication. Changes in viral load have been correlated with antigen-specific responses. We prospectively determined the impact of immunization with 23-valent pneumococcal vaccine (PVAX) and Haemophilus influenzae type b (Hib)-modified diphtheria toxoid CRM197 (DT) vaccine on HIV-1 replication in recent HIV-1 seroconverters (n = 14; median, 5.5 months from infection; median CD4+ T cells, 535 μl), and correlated results with vaccine-related immune activation. Specific antibody responses, markers of CD4+ T cell activation (transferrin and interleukin 2 receptors), and viral burden were measured at weeks -2 (pre), 0, 1, 2, 6, and 12 after immunization. By week 2, levels of IgG had increased significantly over baseline in both HIV-l-infected patients and HIV-l-seronegative control subjects (n = 9) for each antigen (geometric mean fold rise: PVAX, 10.1 versus 5.3; Hib, 16.0 versus 11.7; and DT, 26.2 versus 24.5, respectively). Despite these vigorous responses to both polysaccharide and protein antigens, HIV-1-infected patients showed limited evidence of CD4+ T cell activation at 1 week, no consistent rise in HIV-1 burden at any point, and no decline in CD4+ T cell number over time. We conclude that recent HIV-1 seroconverters show vigorous humoral responses to vaccine antigens and limited early evidence of T cell activation, but no substantial or sustained increase in viral replication or decline in CD4+ T cell number. Thus, respiratory bacterial vaccines appear immunogenic and safe early in HIV-1 infection.

UR - http://www.scopus.com/inward/record.url?scp=0033033384&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033033384&partnerID=8YFLogxK

U2 - 10.1089/088922299310746

DO - 10.1089/088922299310746

M3 - Article

C2 - 10381172

AN - SCOPUS:0033033384

VL - 15

SP - 837

EP - 845

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 9

ER -